|
186 Products |
| 186 Products |
|
1696 Diseases |  |
95004 News |  |
| «12...8889909192939495969798...10641065» |
- ||| Duaklir (aclidinium bromide/formoterol fumarate) / Covis Pharma
Journal, Adverse events: Chronic Obstructive Pulmonary Disease Adverse Event Signals Associated with Potential Inhibitors of Glutathione Peroxidase 1: A Sequence Symmetry Analysis. (Pubmed Central) - Jan 4, 2024
ADE signals were generated for several potential GPx1 inhibitors; however, further validation of signals is required in large well-controlled observational studies.
- | Filspari (sparsentan) / Travere Therap, CSL Behring
Journal: Treatment of IgA nephropathy: a rapidly evolving field. (Pubmed Central) - Jan 4, 2024
While targeted release budesonide has garnered the most attention, anti-B cell strategies and selective complement inhibition will most likely prove their added value. We propose a comprehensive approach that tackles the different targets in the pathophysiology of IgA nephropathy according to their relevance in the individual patient.
- | Zilretta (triamcinolone acetonide ER) / Pacira
Trial primary completion date: Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease (clinicaltrials.gov) - Jan 4, 2024
P3, N=65, Recruiting, Sponsor: Northwell Health
We propose a comprehensive approach that tackles the different targets in the pathophysiology of IgA nephropathy according to their relevance in the individual patient. Trial primary completion date: Dec 2023 --> Dec 2024
- | dexamethasone / Generic mfg.
Enrollment change, Trial termination: Calcific Tendonitis Treatment: Barbotage vs. Barbotage With Cortisone Injection (clinicaltrials.gov) - Jan 4, 2024
P4, N=4, Terminated, Sponsor: NYU Langone Health
Trial primary completion date: Dec 2023 --> Dec 2024 N=150 --> 4 | Recruiting --> Terminated; Enrollment difficulty.
- | dexamethasone / Generic mfg.
Enrollment change: Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation (clinicaltrials.gov) - Jan 4, 2024
P4, N=63, Terminated, Sponsor: Johns Hopkins University
N=150 --> 4 | Recruiting --> Terminated; Enrollment difficulty. N=366 --> 63
- | dexamethasone / Generic mfg., captopril / Generic mfg.
New trial: SubPA-DKD: Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease (clinicaltrials.gov) - Jan 4, 2024
P=N/A, N=125, Not yet recruiting, Sponsor: Brigham and Women's Hospital
- |||| Darzalex Faspro (daratumumab/hyaluronidase) / J&J
New P2 trial, Minimal residual disease: Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS (clinicaltrials.gov) - Jan 4, 2024
P2, N=200, Recruiting, Sponsor: European Myeloma Network
- ||| Zolinza (vorinostat) / Merck (MSD), ziftomenib (KO-539) / Kura Oncology, Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II (clinicaltrials.gov) - Jan 4, 2024
P1/2, N=90, Recruiting, Sponsor: Tanja Andrea Gruber
N=366 --> 63 Not yet recruiting --> Recruiting
- relacorilant (CORT125134) / Corcept Therap
Final overall survival data from a randomized, open-label, phase II study of relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel among patients with recurrent platinum-resistant ovarian cancer (Hall F) - Jan 3, 2024 - Abstract #SGO2024SGO_85;
P2, P3
Not yet recruiting --> Recruiting In the subgroup population similar to that being enrolled in the ROSELLA study (patients with 1
- | dexamethasone / Generic mfg.
Journal: Perioperative dexamethasone in high-grade gliomas: the short-term benefits and long-term harms. (Pubmed Central) - Jan 3, 2024
This perspective article summarizes the disadvantages of perioperative dexamethasone from multiple facets. It concludes that these growing data mandate rigorously testing the benefits of using perioperative dexamethasone.
- || Entereg (alvimopan) / Merck (MSD)
Review, Journal, Surgery: Strategies to reduce ileus after colorectal surgery: A qualitative umbrella review of the collective evidence. (Pubmed Central) - Jan 3, 2024
Intravenous dexamethasone and lidocaine and oral probiotics helped hasten bowel function return. Acupuncture positively impacted the recovery of bowel function.
- | dexamethasone / Generic mfg., celecoxib oral / Generic mfg.
Journal, Cytokine storm: AI-driven Discovery of Celecoxib and Dexamethasone for Exploring their Mode of Action as Human Interleukin (IL-6) Inhibitors to Treat COVID-19-induced Cytokine Storm in Humans. (Pubmed Central) - Jan 3, 2024
The findings of this study have suggested the potential of the drugs studied to be utilized as antagonists for countering CRS in COVID-19 ailment. This study presents the studied drugs as promising candidates both for the clinical and pre-clinical treatment of COVID-19.
- | dexamethasone / Generic mfg.
Journal: Down-regulation of Musashi-2 exerts antileukemic effects on acute lymphoblastic leukemia cells and increases sensitivity to dexamethasone. (Pubmed Central) - Jan 3, 2024
Additionally, the FOXO1/4 signaling pathway contributed to the biological effects of ALL cells evoked by MSI2 silencing. Our study offers novel insight into the inhibitory effects of MSI2 suppression on ALL cells, positing MSI2 as a promising therapeutic target in the treatment of ALL.
- | Darzalex (daratumumab) / J&J
Journal: A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group. (Pubmed Central) - Jan 3, 2024
Similarly, patients treated after Len maintenance showed a better outcome as compared to patients who had received a full-dose Len treatment (23 vs 13 months, p?=?0.1728). In conclusion, our real-world data on D-VD combination showed remarkable efficacy in Len-R patients, placing this regimen as one of the standards of care to be properly taken into account in this MM setting.
- | mometasone furoate / Generic mfg.
Journal: Searching for a "window of opportunity" in the treatment of vulvar lichen sclerosus: evidence for therapeutic benefits of an early corticosteroid treatment. (Pubmed Central) - Jan 3, 2024
Early treatment is crucial in determining a complete healing of VLS-related symptoms and signs, especially of tissue sclerosis-scarring-atrophy, that appear poorly responsive, or even unresponsive, after the earliest stages of the disease. Thus, our findings provide evidence for a 'window of opportunity' in VLS treatment.
- | Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Metastases: CONTRAC: Cemiplimab in AlloSCT/SOT Recipients With CSCC (clinicaltrials.gov) - Jan 3, 2024
P1, N=12, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Thus, our findings provide evidence for a 'window of opportunity' in VLS treatment. Trial completion date: Jan 2024 --> Jan 2025
- | dexamethasone / Generic mfg.
New trial: Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for NARDS (clinicaltrials.gov) - Jan 3, 2024
P=N/A, N=500, Not yet recruiting, Sponsor: The Second Affiliated Hospital of Chongqing Medical University
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Talzenna (talazoparib) / Pfizer
Trial completion date, Trial primary completion date: Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer (clinicaltrials.gov) - Jan 3, 2024
P2, N=70, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Jan 2024 --> Jan 2025 Trial completion date: Dec 2023 --> Aug 2027 | Trial primary completion date: Dec 2023 --> Aug 2027
- | navtemadlin (KRT-232) / Kartos Therap
Trial completion date, Trial primary completion date, Combination therapy: Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma (clinicaltrials.gov) - Jan 3, 2024
P1, N=40, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2023 --> Aug 2027 | Trial primary completion date: Dec 2023 --> Aug 2027 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||| Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
Trial completion, Real-world evidence, Real-world effectiveness, Real-world: To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD (clinicaltrials.gov) - Jan 3, 2024
P4, N=460, Completed, Sponsor: GlaxoSmithKline
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Recruiting --> Completed
- | triamcinolone acetonide / Generic mfg.
Enrollment closed: Comparing Intra-articular Betamethasone (Diprospan) and Triamcinolone Acetonide Injection in Knee Osteoarthritis (clinicaltrials.gov) - Jan 3, 2024
P4, N=105, Active, not recruiting, Sponsor: Thammasat University
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Rybrevant (amivantamab-vmjw) / J&J
Enrollment change: SKIPPirr: Premedication to Reduce Amivantamab Associated Infusion Related Reactions (clinicaltrials.gov) - Jan 3, 2024
P2, N=67, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting N=126 --> 67
- | Epkinly (epcoritamab-bysp) / Genmab, AbbVie
Phase classification, Combination therapy: EPCORE NHL-2: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (clinicaltrials.gov) - Jan 2, 2024
P1/2, N=662, Recruiting, Sponsor: Genmab
N=126 --> 67 Phase classification: P1b/2 --> P1/2
- || triamcinolone acetonide / Generic mfg., clindamycin phosphate / Generic mfg.
Clinical, Review, Journal: Topical and IL therapies for hidradenitis suppurativa: A systematic literature review. (Pubmed Central) - Jan 2, 2024
However, it supports the use of topical clindamycin, PDT, and BTX. Well-designed RCTs with standardized outcomes and homogeneous populations of patients and lesions are needed to support decision-making in the routine clinical practice.
- | dexamethasone injection / Generic mfg.
Preclinical, Journal: Acute exercise modulates Trim63 and Bmal1 in the skeletal muscle of IL-10 knockout mice. (Pubmed Central) - Jan 2, 2024
In conclusion, IL-10 seems to be a determinant in the Rev-erb? pathway and atrophy after acute exercise, with no modulation in the baseline state.
- | dexamethasone / Generic mfg.
Journal: The impact of early tracheostomy on neurodevelopmental outcomes of infants with severe bronchopulmonary dysplasia exposed to postnatal corticosteroids. (Pubmed Central) - Jan 2, 2024
pathway and atrophy after acute exercise, with no modulation in the baseline state. Infants with severe BPD exposed to PCS and had ET had significantly better cognitive, and trend toward improved language and motor outcomes.
- || dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Review, Journal: Smoldering Multiple Myeloma: Observation Versus Control Versus Cure. (Pubmed Central) - Jan 2, 2024
These patients are considered to have high-risk SMM. Patients with newly diagnosed high-risk SMM are candidates for early intervention with lenalidomide or lenalidomide plus dexamethasone for 2
- | simvastatin / Generic mfg., hydrocortisone / Generic mfg.
Journal: Bioinformatics and system biology analysis revealed the crosstalk between COVID-19 and osteoarthritis. (Pubmed Central) - Jan 2, 2024
Patients with newly diagnosed high-risk SMM are candidates for early intervention with lenalidomide or lenalidomide plus dexamethasone for 2 Four hub genes, disease-related miRNAs, TFs, drugs, and immune infiltration help to understand the pathogenesis and perform further studies, providing a potential therapy target for COVID-19 and OA.
- | dexamethasone / Generic mfg.
Journal: N-doped TiO/TiC-driven self-photocatalytic molecularly imprinted ECL sensor for sensitive and steady detection of dexamethasone. (Pubmed Central) - Jan 2, 2024
Four hub genes, disease-related miRNAs, TFs, drugs, and immune infiltration help to understand the pathogenesis and perform further studies, providing a potential therapy target for COVID-19 and OA. Thanks to the heterojunction and self-photocatalytic cyclic amplification, this molecularly imprinted ECL sensor exhibits a wide linear range (1.0
- | dexamethasone / Generic mfg.
Journal: Physical frailty deteriorates after a 5-day dexamethasone course in children with acute lymphoblastic leukemia, results of a national prospective study. (Pubmed Central) - Jan 2, 2024
Physical frailty increased strikingly after a 5-days dexamethasone course in children with ALL. Children with poor physical state at start of the dexamethasone course were more likely to be frail after the course.
- | Nucala (mepolizumab) / GSK
Journal: Eosinophilic granulomatous with polyangiitis complicated by swelling of the oral cavity floor and cervical soft tissue as initial manifestation mimicking IgG4-related disease: A case report. (Pubmed Central) - Jan 2, 2024
The patient's symptoms improved after these treatments, and the eosinophil count and inflammatory marker levels declined. When swelling of the oral cavity floor and cervical soft tissue following an increase in eosinophilia and allergic symptoms occurs, it is crucial to consider the likelihood of eosinophilic granulomatous polyangiitis and collaborate with otolaryngologists and dentists to ensure its prompt identification.
- | hydrocortisone / Generic mfg.
Journal: Hydrocortisone for severe community acquired pneumonia in ICU. (Pubmed Central) - Jan 2, 2024
When swelling of the oral cavity floor and cervical soft tissue following an increase in eosinophilia and allergic symptoms occurs, it is crucial to consider the likelihood of eosinophilic granulomatous polyangiitis and collaborate with otolaryngologists and dentists to ensure its prompt identification. No abstract available
- | pemetrexed / Generic mfg.
Trial completion date: Intrathecal Pemetrexed for Leptomeningeal Metastasis (clinicaltrials.gov) - Jan 1, 2024
P1/2, N=34, Active, not recruiting, Sponsor: The First Hospital of Jilin University
- | dexamethasone injection / Generic mfg.
Trial completion date, Trial primary completion date: The Use of Dexamethasone in Total Thyroidectomy to Improve Voice Outcome and Hypocalcaemia (clinicaltrials.gov) - Dec 31, 2023
P2, N=100, Not yet recruiting, Sponsor: Tseung Kwan O Hospital, Hong Kong
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion date, Trial primary completion date: IDAR: Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial (clinicaltrials.gov) - Dec 31, 2023
P2/3, N=86, Not yet recruiting, Sponsor: Assistance Publique - H
- || Sarclisa (isatuximab-irfc) / Sanofi
Trial completion date, Trial primary completion date, Combination therapy: Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ?70 Years) With NDMM (clinicaltrials.gov) - Dec 31, 2023
P2, N=198, Recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
- ||| relacorilant (CORT125134) / Corcept Therap
Trial completion date, Trial primary completion date: GRACE: A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome (clinicaltrials.gov) - Dec 31, 2023
P3, N=152, Active, not recruiting, Sponsor: Corcept Therapeutics
- || relacorilant (CORT125134) / Corcept Therap
Trial completion date, Trial primary completion date: Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome (clinicaltrials.gov) - Dec 31, 2023
P2, N=75, Enrolling by invitation, Sponsor: Corcept Therapeutics
- | hydrocortisone / Generic mfg.
Journal: Potentials of Gynura procumbens to modulate chronic stress and immunological responses in Oreochromis niloticus. (Pubmed Central) - Dec 31, 2023
Hydrocortisone (0.01% of body weight) was incorporated with the feed to induce the stress response in stress, prevention and treatment groups...The result is substantiated by significant decrease in blood glucose level in prevention (29.5 mg/dL; p = 0.002) and treatment (31.5 mg/dL; p = 0.006) groups, compared to stress group (47.33 mg/dL) at the end of the experiment. Considering the current finding, we can conclude the GPE has potential to be used as therapeutic option for stress regulation however there is a room for further detailed study to understand the in-depth mechanism.
- | dexamethasone / Generic mfg.
Preclinical, Journal: Dexamethasone restores TNF?-induced epithelial barrier dysfunction in primary rat alveolar epithelial cells. (Pubmed Central) - Dec 31, 2023
Further investigation revealed that Dex enhanced the expression of zonula occludens-1 (ZO-1), a tight junction-related protein, at intercellular junction sites. These findings suggest that GCs strengthen the integrity of the alveolar epithelial barrier in ALI/ARDS via the GR-MLCK-pMLC2 axis.
- | Decadron (dexamethasone) / Merck (MSD), Darzalex (daratumumab) / J&J
Trial completion date, Trial primary completion date: 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy (clinicaltrials.gov) - Dec 31, 2023
P2, N=50, Active, not recruiting, Sponsor: University of Arkansas
- | Empliciti (elotuzumab) / AbbVie, BMS, iberdomide (CC-220) / BMS
Trial completion date, Trial primary completion date, Combination therapy: A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 31, 2023
P1, N=31, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
- | Polivy (polatuzumab vedotin-piiq) / Roche
Trial completion date, Trial primary completion date: Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Dec 31, 2023
P2, N=44, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
- | carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation (clinicaltrials.gov) - Dec 31, 2023
P2, N=29, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Trial primary completion date, Minimal residual disease: Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 31, 2023
P2, N=32, Recruiting, Sponsor: St. Jude Children's Research Hospital
- | dexamethasone / Generic mfg., dexmedetomidine / Generic mfg.
Journal, Surgery: Effects of epidurally administered dexmedetomidine and dexamethasone on postoperative pain, analgesic requirements, inflammation, and oxidative stress in thoracic surgery. (Pubmed Central) - Dec 30, 2023
Both dexmedetomidine and dexamethasone exhibited antioxidant effects, however, their antioxidant properties should be further explored. The results of this study improve current knowledge of pain control in thoracic surgery.
- | Rinvoq (upadacitinib) / AbbVie
Trial completion date, Trial primary completion date: A Trial for Acute Severe Ulcerative Colitis (clinicaltrials.gov) - Dec 30, 2023
P4, N=162, Recruiting, Sponsor: Berinstein, Jeffrey
- floxuridine / Generic mfg.
A Prospective Evaluation of a Modified Hepatic Arterial Infusion Floxuridine Reduced-Dose Protocol for Patients with Unresectable Colorectal Liver Metastases () - Dec 29, 2023 - Abstract #SSO2024SSO_409;
Learning Objectives: Describe the benefits a dose-reduced protocol of hepatic arterial infusion of floxuridine provides compared to standard dose protocol in the treatment of patients with unresectable colorectal liver metastasis Discuss the difference in biliary toxicity between a dose-reduced protocol of floxuridine compared to the standard floxuridine dosing protocol. Identify patients in their own practice with unresectable colorectal cancer liver metastases hat may potentially benefit from HAI floxuridine therapy.
- | dexamethasone / Generic mfg.
Journal: Assessment of the Effectiveness of Corticosteroid Infiltrations in the Ignace Deen University Hospital Center in Conakry. (Pubmed Central) - Dec 29, 2023
Dexamethasone was the corticosteroid predominantly used in 46.2% of cases...The study demonstrated the efficacy of cortisone infiltration, with improvement in pain intensity in some patients (70% of cases). For others, however, the pain remained unchanged.
- | dexamethasone / Generic mfg.
Journal: Antagonistic regulation of homeologous uncx.L and uncx.S genes orchestrates myotome and sclerotome differentiation in the evolutionarily divergent vertebral column of Xenopus laevis. (Pubmed Central) - Dec 29, 2023
Additionally, we employed gain-of-function and loss-of-function approaches through dexamethasone-inducible uncx constructs and antisense morpholino oligonucleotides, respectively...Postallotetraploidization, the uncx.L gene in X. laevis evolved to lose its eh1-like repressor domain, transforming into a "native dominant negative" variant that potentially competes with uncx.S for the same target genes. Finally, the histological analysis revealed that uncx.S expression is necessary for the correct formation of pedicles and neural arch of the vertebrae, and uncx.L is required for trunk muscle development.